奥马珠单抗治疗系统性红斑狼疮的安全性与耐受性随机临床试验
一项随机、安慰剂对照试验纳入16例SLEDAI-2K≥4且自身反应性IgE升高的轻中度SLE患者,按2:1接受奥马珠单抗或安慰剂16周,随后16周开放标签治疗及4周洗脱。奥马珠单抗耐受良好,无过敏反应,不良事件多为轻度且与安慰剂相当;第16周SLEDAI-2K较安慰剂组改善(P=0.038),开放标签阶段初始安慰剂组亦改善(P=0.02)。
要点
- 奥马珠单抗在轻中度SLE中耐受良好,不良事件多为轻度且与安慰剂相当。
- 第16周SLEDAI-2K较安慰剂组显著改善(P=0.038),开放标签阶段初始安慰剂组亦改善(P=0.02)。
- I型干扰素基因特征呈下降趋势(P=0.11),高基线干扰素特征者P=0.052。
核心结论
- 奥马珠单抗在SLE中耐受良好,并与疾病活动度改善相关,但需更大规模随机临床试验评估疗效。
研究设计与样本
- 随机、安慰剂对照试验纳入16例SLEDAI-2K≥4且自身反应性IgE抗体升高的SLE患者,按2:1随机接受奥马珠单抗或安慰剂16周,随后16周开放标签治疗及4周洗脱期。
主要发现
- 奥马珠单抗耐受良好,无过敏反应,不良事件多为轻度且与安慰剂相当。
- 第16周SLEDAI-2K在奥马珠单抗组较安慰剂组改善(P=0.038),开放标签阶段初始安慰剂组亦改善(P=0.02)。
- 未检测到BILAG评分或医生整体评估恶化。
- I型干扰素基因特征在奥马珠单抗治疗者呈下降趋势(P=0.11),高基线干扰素特征者P=0.052。
关键数值与推荐
- 入组标准为SLE且SLEDAI-2K评分≥4、自身反应性IgE抗体水平升高。
- 主要疗效比较为第16周SLEDAI-2K评分变化,奥马珠单抗组 vs 安慰剂组 P=0.038。
临床怎么用
- 结果支持奥马珠单抗在轻中度SLE中耐受良好,但疗效证据尚需更大规模随机对照试验确认,暂不宜作为常规治疗推荐。
局限性
- 样本量小(16例),随访时间有限,需更大规模随机临床试验评估疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Autoreactive IgE antibodies have been implicated in the pathogenesis of systemic lupus erythematosus (SLE). We hypothesize that omalizumab, a monoclonal antibody binding IgE, may improve SLE activity by reducing type I interferon (IFN) production by hampering plasmacytoid dendritic cells and basophil activation. This study was undertaken to assess the safety, tolerability, and clinical efficacy of omalizumab in mild to moderate SLE. METHODS: Sixteen subjects with SLE and a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of ≥4 and elevated autoreactive IgE antibody levels were randomized to receive omalizumab or placebo (2:1) for 16 weeks, followed by 16 weeks of open-label treatment and a 4-week washout period. The SLEDAI-2K score, British Isles Lupus Assessment Group index (BILAG 2004) score, and physician's global assessment of disease activity were recorded at each visit. The type I IFN-induced gene signature was determined using quantitative polymerase chain reaction. RESULTS: Omalizumab was well tolerated with no allergic reactions, and mostly mild adverse events comparable to those experienced with placebo treatment. SLEDAI-2K scores improved in the omalizumab group compared to the placebo group at week 16 (P = 0.038), as well as during the open-label phase in subjects initially receiving placebo (P = 0.02). No worsening in BILAG scores or the physician's global assessment was detected. There was a trend toward a reduction in IFN gene signature in subjects treated with omalizumab (P = 0.11), especially in subjects with a high baseline IFN signature (P = 0.052). CONCLUSION: Our findings indicate that omalizumab is well tolerated in SLE and is associated with improvement in disease activity. Larger randomized clinical trials will be needed to assess the efficacy of omalizumab in patients with SLE.
引用
- Hasni S, Gupta S, Davis M, et al. Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019. PMID: 30597768. doi:10.1002/art.40828
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。